<DOC>
	<DOC>NCT00427284</DOC>
	<brief_summary>The aim of the present study is to investigate wether endothelial dysfunction associated with stable coronary artery disease is altered by selective aldosterone antagonism with Eplerenone as potential anti-inflammatory drug versus placebo. Additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as C-reactive proteine, oxidative stress and pro-inflammatory cytokines.</brief_summary>
	<brief_title>Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Inclusion criteria: Male patients (&gt; 30 years of age) with history of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test) Stable cardiovascular medication for at least 4 months Evaluation of the patients will take place at the Department of Internal Medicine, Cardiology, University Hospital Zurich. Exclusion criteria: Evidence for myocardial infarction, unstable angina, stroke within 3 months prior to study entry coronary intervention/revascularisation procedure within 3 months prior to study entry long acting nitrates uncontrolled arterial hypertension, defined as RR&gt;160/90 mmHg congestive heart failure (&gt; NYHA I) Ejection fraction &lt;50% AVBlock&gt;IËš creatinine clearance &lt;50 mL/min insulindependent diabetes mellitus type 2 diabetes with microalbuminuria age &lt; 30 years anemia (Hb&lt;10 g/dl) malignancy chronic infection smoking serum potassium &gt;5.5 meq/L drug abuse potassium supplements or potassiumsparing diuretics (amiloride, spironolactone, or triamterene) concomitant use of strong inhibitors of CYP450 3A4 (e.g., ketoconazole, itraconazole) known history of Cushing disease or Morbus Addisons or diseases of the thyroid gland</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Eplerenone auf die Endothelfunktion bei Patienten mit stabiler koronarer Herzkrankheit</keyword>
</DOC>